LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1841 | 5578 | 0.3301 | -0.2312 |
| SK-BR-3 | Celastrol | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1758 | 5578 | 0.3152 | -0.2587 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 1225 | 5578 | 0.2196 | -0.4344 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1251 | 5578 | 0.2244 | -0.4256 |
| SK-BR-3 | CHIR-99021 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 4353 | 5578 | 0.7804 | 0.5963 |
| SK-BR-3 | CP724714 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 2800 | 5578 | 0.5019 | 0.0845 |
| SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5881 | 5578 | 1.0543 | 1.0997 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 4743 | 5578 | 0.8503 | 0.7249 |
| SK-BR-3 | Momelotinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 4832 | 5578 | 0.8662 | 0.7540 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5011 | 5578 | 0.8984 | 0.8132 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 4602 | 5578 | 0.8251 | 0.6784 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 4209 | 5578 | 0.7545 | 0.5489 |
| SK-BR-3 | Enzastaurin | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5864 | 5578 | 1.0513 | 1.0942 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5616 | 5578 | 1.0068 | 1.0125 |
| SK-BR-3 | Foretinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 2136 | 5578 | 0.3829 | -0.1342 |
| SK-BR-3 | R406 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 5424 | 5578 | 0.9723 | 0.9490 |
| SK-BR-3 | Pictilisib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 2194 | 5578 | 0.3934 | -0.1149 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 3564 | 5578 | 0.6390 | 0.3365 |
| SK-BR-3 | Geldanamycin | 1.11 | uM | LJP5 | 72 | hr | 2543 | 2371 | 5578 | 0.4250 | -0.0568 |
| SK-BR-3 | Geldanamycin | 1.11 | uM | LJP6 | 72 | hr | 2543 | 2174 | 5578 | 0.3898 | -0.1215 |
| SK-BR-3 | GSK1059615 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 2580 | 5578 | 0.4625 | 0.0121 |
| SK-BR-3 | GSK1059615 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 2143 | 5578 | 0.3842 | -0.1318 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 72 | hr | 2543 | 5536 | 5578 | 0.9925 | 0.9862 |
| SK-BR-3 | Omipalisib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1289 | 5578 | 0.2312 | -0.4131 |
| SK-BR-3 | GSK 690693 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 4188 | 5578 | 0.7507 | 0.5418 |